This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (13)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Venous Thromboembolism  • Cardiovascular System  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Intern Med. 2002;162:2521-2523.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE FIRST clinical report of the use of a thrombolytic agent (streptokinase) to treat acute pulmonary embolism (PE) appeared in 1964,¹ and the first randomized clinical trial comparing urokinase plus heparin with heparin alone was published in 1970.² A randomized clinical trial comparing urokinase to streptokinase in the treatment of PE was published in 1974.³ The first report of a third thrombolytic agent, recombinant tissue-type plasminogen activator, in the treatment of acute PE was published by Bounameaux et al⁴ in 1985. The US Food and Drug Administration approved streptokinase in 1977, urokinase in 1978, and recombinant tissue-type plasminogen activator in 1990 for the treatment of acute PE.⁵ Despite more than 3 decades of experience with these thrombolytic agents, their role in the treatment of PE remains uncertain and controversial.

The article by Agnelli et al⁶ in this issue of the ARCHIVES presents a clinical outcome–based meta-analysis of thrombolysis vs heparin . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Thrombolysis in the Treatment of Submassive Pulmonary Embolism
Luca Mascitelli and Francesca Pezzetta
Arch Intern Med. 2003;163(10):1238.
EXTRACT | FULL TEXT  

Thrombolysis in the Treatment of Submassive Pulmonary Embolism—Reply
James E. Dalen
Arch Intern Med. 2003;163(10):1238.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Thrombolysis vs Heparin in the Treatment of Pulmonary Embolism: A Clinical Outcome–Based Meta-analysis
Giancarlo Agnelli, Cecilia Becattini, and Timo Kirschstein
Arch Intern Med. 2002;162(22):2537-2541.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Haemodynamically unstable pulmonary embolism in the RIETE Registry: systolic blood pressure or shock index?
Otero et al.
Eur Respir J 2007;30:1111-1116.
ABSTRACT | FULL TEXT  

Right Ventricular Dysfunction
King
Chest 2005;127:1458-1459.
FULL TEXT  

Initial Treatment of Venous Thromboembolism
McRae and Ginsberg
Circulation 2004;110:I-3-I-9.
ABSTRACT | FULL TEXT  

Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism: A Meta-Analysis of the Randomized Controlled Trials
Wan et al.
Circulation 2004;110:744-749.
ABSTRACT | FULL TEXT  

Prognostic Value of Echocardiographically Assessed Right Ventricular Dysfunction in Patients With Pulmonary Embolism
ten Wolde et al.
Arch Intern Med 2004;164:1685-1689.
ABSTRACT | FULL TEXT  

Thrombolysis in the Treatment of Submassive Pulmonary Embolism
Mascitelli and Pezzetta
Arch Intern Med 2003;163:1238-1238.
FULL TEXT  

Thrombolysis in the Treatment of Submassive Pulmonary Embolism--Reply
Dalen
Arch Intern Med 2003;163:1238-1238.
FULL TEXT